Author: Sigalov, Alexander B.
Title: Targeting Intramembrane Protein–Protein Interactions: Novel Therapeutic Strategy of Millions Years Old Cord-id: sfd6wbjp Document date: 2017_7_24
ID: sfd6wbjp
Snippet: Intramembrane protein–protein interactions (PPIs) are involved in transmembrane signal transduction mediated by cell surface receptors and play an important role in health and disease. Recently, receptor-specific modulatory peptides rationally designed using a general platform of transmembrane signaling, the signaling chain homooligomerization (SCHOOL) model, have been proposed to therapeutically target these interactions in a variety of serious diseases with unmet needs including cancer, seps
Document: Intramembrane protein–protein interactions (PPIs) are involved in transmembrane signal transduction mediated by cell surface receptors and play an important role in health and disease. Recently, receptor-specific modulatory peptides rationally designed using a general platform of transmembrane signaling, the signaling chain homooligomerization (SCHOOL) model, have been proposed to therapeutically target these interactions in a variety of serious diseases with unmet needs including cancer, sepsis, arthritis, retinopathy, and thrombosis. These peptide drug candidates use ligand-independent mechanisms of action (SCHOOL mechanisms) and demonstrate potent efficacy in vitro and in vivo. Recent studies surprisingly revealed that in order to modify and/or escape the host immune response, human viruses use similar mechanisms and modulate cell surface receptors by targeting intramembrane PPIs in a ligand-independent manner. Here, I review these intriguing mechanistic similarities and discuss how the viral strategies optimized over a billion years of the coevolution of viruses and their hosts can help to revolutionize drug discovery science and develop new, disruptive therapies. Examples are given.
Search related documents:
Co phrase search for related documents- adaptive immune response and low expression: 1, 2
- adaptive immune response and low expression patient: 1
- adaptive immune response and lung cancer: 1
- adaptive immune response and lupus erythematosus: 1
- adaptive immune response and macrophage activation: 1, 2
- adaptive immune response and macrophage expression: 1, 2
- adaptive immune response and macrophage infiltration: 1
- adaptive immune response and macrophage specific: 1
- adaptive innate and low activity: 1, 2
- adaptive innate and low expression: 1, 2, 3, 4, 5, 6, 7, 8
- adaptive innate and low expression patient: 1, 2
- adaptive innate and lung cancer: 1, 2, 3, 4, 5, 6, 7
- adaptive innate and lupus erythematosus: 1, 2, 3, 4, 5, 6, 7
- adaptive innate and lymphatic vascular: 1
- adaptive innate and lymphatic vascular system: 1
- adaptive innate and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- adaptive innate and macrophage expression: 1, 2, 3, 4
- adaptive innate and macrophage infiltration: 1, 2
- adaptive innate and macrophage specific: 1, 2
Co phrase search for related documents, hyperlinks ordered by date